Nov 19 (Reuters) – Celldex Therapeutics said on Thursday it would stop developing its experimental drug for eczema after the treatment failed to meet the main and key secondary goals of a mid-stage study.
Shares of the company were down over 3% in extended trading.
• The study enrolled 131 patients with moderate-to-severe atopic dermatitis, a chronic inflammatory skin condition commonly known as eczema
• The drug, barzolvolimab, did not significantly reduce itching after 16 weeks and showed no meaningful improvement over placebo on other key measures
• The drug reduced mast cells, immune cells involved in allergic and inflammatory reactions, but the results suggest they are not the main driver of atopic dermatitis, the company said
• Celldex said the limited improvements fell short of its threshold for further development, with no added benefit after 32 weeks
• The treatment was well tolerated, with a safety profile consistent with earlier studies
• Celldex will continue late-stage studies of barzolvolimab in three hive-related skin conditions: chronic spontaneous urticaria, cold urticaria and symptomatic dermographism
• The company plans to seek US approval for the drug in chronic spontaneous urticaria in 2027 and announce additional indications by year-end
(Reporting by Kunal Das in Bengaluru; Editing by Shinjini Ganguli and Perla Velasco)

